Ling Chen | Professor
Guangzhou Medical University,Guangzhou, China

Dr Ling CHEN received his medical degree from Shanghai Medical College in 1984. He received his PhD in Biochemistry and Molecular Biology from Indiana University School of Medicine, USA in 1992. Dr Chen completed his postdoctoral training in 1994 at the Dana-Farber Cancer Institute, Harvard Medical School, where he then served as an Instructor from 1994 to 1996.  From 1997 to 2001, Dr Chen was a Senior Research Fellow at Merck Research Laboratories, where he championed MRK Ad5-based AIDS vaccine. From 2008 to 2012, Dr Chen served successively as VP of R&D China at GSK and Sanofi-Pasteur China Vaccine R&D. He is also a Hornored Investigator and was the founding Director General (2004-2008) of the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences. Dr Chen has over 200 publications in infectious diseases, vaccine research and cancer research. He has been instrumental in the development of an adenovirus vectored SARS-CoV-2 nasal vaccine, which has completed a Phase I clinical trial and an Investigator Initiated Trial.  His recent research interest include mucosal vaccines, human antibody response and antibody repertoire, and developing novel shark-derived nanobodies as antiviral agents.